Exact Sciences has launched Cologuard Plus™, a new FDA-approved, noninvasive colorectal cancer (CRC) screening test for average-risk adults aged 45+. Backed by data from the BLUE-C study, the test shows 95% sensitivity for CRC and 94% specificity, making it the most accurate noninvasive CRC test to date. Compared to the original Cologuard, it reduces false positives by 40%, detects more precancerous lesions, and improves confidence in negative results.
Exact Sciences Launches the Cologuard™ Plus Test, Transforming Colorectal Cancer Screening (Exact Sciences )
0